Dépistages... pas si simple !!!
29 octobre 2009
Rethinking Screening for Breast Cancer
and Prostate Cancer
JAMA. 2009;302(15):1685-1692
After 20 years of screening for breast and prostate cancer, several observations
can be made. - First, the incidence of these cancers increased after
the introduction of screening but has never returned to prescreening levels.
- Second, the increase in the relative fraction of early stage cancers has increased.
- Third, the incidence of regional cancers has not decreased at a commensurate
rate.
One possible explanation is that screening may be increasing
the burden of low-risk cancers without significantly reducing the burden
of more aggressively growing cancers and therefore not resulting in the anticipated
reduction in cancer mortality. To reduce morbidity and mortality
from prostate cancer and breast cancer, new approaches for screening, early
detection, and prevention for both diseases should be considered.
[Lire]
Prostate screening in France
Published 21 October 2009 BMJ 2009;339:b4285
Everywhere, practice guidelines are up to date and clearly cite the unproved benefit of screening for prostate specific antigen, as well as the adverse effects (high risk of overdiagnosis and overtreatment). Everywhere, that is, but in France. For the fifth consecutive year, French urologists are actively promoting prostate cancer screening, despite the arguments.
[Lire]
 | . |
 |
